VEGFA and hepatocellular carcinoma: In the landmark IMBrave150 trial (the first ever successful phase III trial of ICIs in advanced HCC), atezolizumab (an anti-PD-L1) combined with bevacizumab (an anti-VEGF monoclonal antibody) was compared against sorafenib in the first-line setting.